Assessing the Patient Experience in Cancer Care

NCT ID: NCT01621295

Last Updated: 2016-01-20

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 408 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2015-09-30

Brief Summary

Communication is an important component of comprehensive cancer care impacting patient satisfaction, adherence, and quality of life. The wide array of issues addressed in cancer clinical interactions makes communicating about a broad range of topics (including quality of life, communication, symptom control, complementary/alternative therapies, costs, treatment burden, prognosis, anxiety, side-effects, sexual function, palliative care options, etc.) especially interesting and potentially challenging. Some of these topics may not be routinely addressed in the clinical interaction or may require consultative support from other members of the comprehensive cancer care team. One frequently overlooked critical element in research on communication between cancer clinicians, their patients, and their primary care clinicians is describing real-time consultations between patients and their clinicians. These interactions provide rich material for assessing key psycho-social dynamics and identifying issues that patients find important in their care. In order to devise systems of care that optimize the patient experience, it is critical that clinicians and researchers understand, appreciate, and systematically characterize the richness and complexity of the decision-making process in routine cancer consultations between cancer patients and their treating clinicians. This study seeks to assess the patient experience in cancer care by observing patients and their physicians in their clinical interactions and following them for several months to see how their care went. By describing in-depth the conversations and experiences of patients in these clinical interactions, this study will lay the foundation for practice-based interventions to optimize patients' interactions with their cancer care teams.

Conditions

Brain Neoplasm; Breast Neoplasm; Endocrine Gland Neoplasm; Gastrointestinal Neoplasm; Genitourinary Neoplasm; Gynecological Neoplasm; Head and Neck Neoplasm; Lung Neoplasm; Melanoma; Sarcoma

Eligibility Criteria

Inclusion Criteria

• Age greater than or equal to 18 years
• Histological confirmation of: brain, breast, endocrine, gastrointestinal, genitourinary, gynecological, head/neck, lung, melanoma, or sarcoma malignancies.
• Speak English or Spanish
• Not enrolled in hospice
• In any of the following phases of the cancer control continuum: initial diagnosis, initial treatment, early survivorship, or recurrence.
• Provide written informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Southern California

OTHER

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Jon C. Tilburt

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jon C Tilburt, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Los Angeles County Hospital

Los Angeles, California, United States

University of Southern California - Norris

Los Angeles, California, United States

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

R01AT006515

Identifier Type: NIH

Identifier Source: secondary_id

View Link

11-006682

Identifier Type: -

Identifier Source: org_study_id